Drug
Latozinemab clinical trials
Also written AL001.
Keep track of what changes. Save the latozinemab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
9 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 2 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 0
Alector Inc. (4) · Alzamend Neuro, Inc. (3) · Beijing Anlong Biopharmaceutical Co., Ltd. (2)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses latozinemab is read from its arms, and is right about nine times in ten.
Testing it · 9
- A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I DisorderRecruitingPhase 1/2Alzamend Neuro, Inc.NCT07540338Written as AL001
- Efficacy and Safety of AL-001 Ophthalmic Injection in Subjects with WAMDNot yet recruitingPhase 2Beijing Anlong Biopharmaceutical Co., Ltd.NCT06839339Written as AL-001
- A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Healthy Adult SubjectsCompletedPhase 1Alzamend Neuro, Inc.NCT06921590Written as AL001
- Continuation Study for LatozinemabTerminatedPhase 3Alector Inc.NCT06111014Written as Latozinemab
- A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)CompletedPhase 2Alector Inc.NCT03987295Written as AL001
- A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALSTerminatedPhase 2Alector Inc.NCT05053035Written as AL001
- Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult SubjectsCompletedPhase 1/2Alzamend Neuro, Inc.NCT05363293Written as AL001
- Safety and Tolerability of AL-001 Ophthalmic Injection in Subjects with WAMDActive, not recruitingPhase 1/2Beijing Anlong Biopharmaceutical Co., Ltd.NCT06707753Written as AL-001
- A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) MutationCompletedPhase 1Alector Inc.NCT03636204Written as AL001
Codes
What other systems call latozinemab · ClinicalTrials.gg INT016858
- UNII (FDA) IKT0XSS2XBLATOZINEMABOne source FDA
- NCI Thesaurus C179098LatozinemabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | IKT0XSS2XB | LATOZINEMAB | One source FDA |
| NCI Thesaurus | C179098 | Latozinemab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.